|
Ophthalmology Newsletter
|
 |
 |
 |
|
Newsletter sponsor
|
|
Dr. Jay Katz discusses the efficacy, safety, compliance and cost advantages of SLT and concludes that it is a reasonable choice as first-line therapy for certain glaucoma patients.
In this webinar you will learn:
- How SLT compares to medication
therapy with regard to IOP reduction
- Safety and compliance considerations
for each treatment option
- Which treatment option is more cost effective to patients as a first-line option
|
| |
| |
|
|
|
|
Copyright© 2026 OphthalmologyWeb. All rights reserved.
This information is being brought to you because you
are a subscriber to OphthalmologyWeb.
unsubscribe
395 Oyster Point Blvd., Suite 321
South San Francisco, CA 94080 |
|